Votre panier

Votre panier est actuellement vide.

Psychedelic News, November 2026: Ballots, the FDA and Ibogaine Funding

THE GOD SOURCE Microfleece Cloak by Salvia Droid

If you read our state-by-state psilocybin reality check back in August, the first half of November added several new dates to that story. Voters weighed in on Nov. 3, Compass Pathways completed its psilocybin drug application on Nov. 9, and on Nov. 12 the federal government announced new research money for ibogaine. Here is what happened, with every figure dated and sourced. Nothing here is medical advice, and none of it changes what is legal where you live.

Idaho Says No to HJR 4

The biggest psychedelics-related vote on Nov. 3 was not a legalization measure at all. Idaho's House Joint Resolution 4 asked voters to amend the state constitution so that "only the Idaho Legislature" could legalize marijuana, narcotics or "other psychoactive substances." That would have taken the question away from citizen ballot initiatives.

Voters rejected it. Unofficial results from the Idaho Secretary of State, last updated Nov. 10, show 472,957 votes against (66.26%) and 240,832 in favour (33.74%). The result keeps the initiative route open in Idaho. It does not legalize anything.

Three Oregon Towns Keep Psilocybin Businesses Out

Oregon voters approved licensed psilocybin services through Measure 109 in 2020, but local voters can still keep those businesses out of their towns, and some keep doing so.

  • Redmond extended its moratorium on psilocybin service centers for another two years. Deschutes County's unofficial results, updated Nov. 13, show Measure 9-186 passing 8,870 to 6,813 (56.56%). The Redmond Spokesman notes it is the third time city voters have backed a moratorium, after 53% in 2022 and 55% in 2024.
  • Reedsport approved Measure 10-215, a ban on psilocybin-related businesses, with about 65.5% voting yes in unofficial Oregon Secretary of State figures reported by KOBI-TV on Nov. 10.
  • Joseph voted 414 to 279 to continue its ban on psilocybin-related businesses, according to unofficial results reported by the Wallowa County Chieftain.

All of these counts are unofficial until certified.

Compass Completes Its Psilocybin NDA

On Nov. 9, Compass Pathways announced that it had finished submitting its New Drug Application to the U.S. FDA for COMP360, its synthetic psilocybin formulation, for treatment-resistant depression. The company says the filing draws on two Phase 3 trials and a Phase 2b study with more than 1,000 participants in total. It is planning for a U.S. launch in the first half of 2027, subject to FDA approval.

Two cautions belong right next to that headline. First, a filing is not an approval. Psychiatric Times notes that if it is approved, COMP360 would be the first classic psychedelic medicine the FDA has ever approved. Second, psilocybin is still a Schedule I controlled substance under federal law, so, as Drug Discovery & Development reports, the DEA would have to reschedule it before any launch, and state rules could affect where it is available.

Compass is not alone. Trade publication Psychedelic Alpha reported on Nov. 2, citing sources, that the nonprofit Usona Institute had filed its own psilocybin application for major depressive disorder. Usona declined to comment on that report.

The Fast-Track Question

Both Compass and Usona hold Commissioner's National Priority Vouchers, an FDA pilot program meant to cut some reviews to one or two months. On Nov. 12, Reuters reported, citing six sources and internal documents, that the FDA has shelved that program and has awarded no new vouchers since former Commissioner Marty Makary left in May. An HHS spokesperson told Reuters the pilot is ongoing. Psychedelic Alpha expects the FDA to try to honour existing vouchers but says it is not yet clear how things will proceed. In short, the timing of any decision is uncertain.

HHS Puts Money Into Ibogaine Groundwork

Also on Nov. 12, HHS announced up to $4.9 million over five years through ARPA-H to prepare ibogaine for possible future U.S. studies in PTSD. The teams are led by the Mark Cuban Cost Plus Drug Company and Beond, Inc. HHS is explicit about the limits: the money funds regulatory and manufacturing groundwork, not patient treatment or human-subject research, and it does not authorize clinical trials or establish FDA approval. HHS also states plainly that ibogaine carries serious safety risks, including potentially life-threatening heart rhythm problems.

Separately, the National Institute of Mental Health posted a $20 million funding opportunity for a research network on rapid-acting psychotropic drugs, including ketamine, esketamine and psilocybin. Awards are expected in summer 2027.

What This Means for Psychedelic Culture

None of this changes the law for an individual in most of the U.S., and, as the ROM notes, most psychedelics remain illegal in Canada. What it does change is the conversation. Psychedelic art and trippy clothing have always borrowed from the same visual language that is now showing up in courtrooms, ballot booklets and federal press releases. That language includes mandalas, fractals and sacred geometry. We will keep tracking the facts, and we will keep making room for the art.

Wear the Art, Follow the Story

The Salvia Droid designs in our shop carry that visionary imagery into everyday layers:

Shop psychedelic art you can wear at acidmath.com, where every design comes from an artist we work with directly.


Sources

Article précédent
Poste suivant

Laissez un commentaire

Featured stories